<!DOCTYPE HTML>

<html>
<head>
<title> Summary + Date</title>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1, user-scalable=no" name="viewport"/>
<link href="assets/css/sum_pg.css" rel="stylesheet"/>
</head>
<body class="is-preload">
<!-- Header -->
<header id="header">
<h1 style="margin-top: 0 !important; padding-top: 0 !important;">MAD MONEY Summaries</h1>
<!-- <p>AI-generated summaries for the show Mad Money hosted by Jim Cramer. -->
<h2 id="show_date_append_here"> </h2>
<p id="append_audio_link_here"> </p>
</header>
<!-- Place acc summary here -->
</body>
<body id="append_here">
Jim Cramer's Mad Money Recap
Segment 1: Market Recap
<ul>
<li>Splunk (SPLK) reports strong quarter, CEO Chuck Robbins buys shares, indicating confidence.</li>
<li>Vistra (VST) considered high-risk due to volatility, Cramer cautious.</li>
<li>Larry Williams' cycle analysis predicts market downturn, potential buying opportunity.</li>
<li>Enterprise software struggles, Nvidia (NVDA) crucial for market direction.</li>
</ul>
Segment 2: Confluent Interview
<ul>
<li>Confluent (CFLT) CEO Jay Kreps discusses Q2 results: 27% growth, record new logo additions.</li>
<li>Pressure in digital native segment impacts guidance, cautious outlook.</li>
<li>Walmart uses Confluent for real-time inventory management, competitive edge.</li>
<li>German company uses Confluent to handle customer calls, improving efficiency.</li>
<li>Cramer likes Confluent's long-term potential, but awaits clearer guidance.</li>
</ul>
Segment 3: Lightning Round
<ul>
<li><strong>Flutter (FLTR)</strong>: Buy before football season, potential upside.</li>
<li><strong>ASML (ASML)</strong>: Too expensive, wait for pullback.</li>
<li><strong>PayPal (PYPL)</strong>: Financials improving, potential buy.</li>
<li><strong>Liquidia (LQDA)</strong>: Too speculative, avoid.</li>
<li><strong>Crown Castle (CCI)</strong>: Not enough growth, consider alternatives.</li>
<li><strong>Tesla (TSLA)</strong>: Elon Musk's influence drives stock, be cautious.</li>
</ul>
Segment 4: Eli Lilly
<ul>
<li>Eli Lilly's (LLY) revolutionary weight loss and diabetes drug shows promising results.</li>
<li>94% reduction in type 2 diabetes risk, significant potential.</li>
<li>Average patient lost 23% body weight, impressive efficacy.</li>
<li>Potential for FDA approval and insurance coverage, significant catalyst.</li>
<li>Competitors lagging behind, Eli Lilly's lead significant.</li>
<li>Potential uses: congestive heart failure, liver disease, hypertension, alcoholism.</li>
<li>Cramer bullish on Eli Lilly's long-term potential.</li>
</ul>
Closing Remarks
<ul>
<li>Eli Lilly's drug pipeline has vast potential, significant growth opportunity.</li>
<li>Importance of discipline and homework in investing, crucial for success.</li>
<li>Cramer emphasizes patience, long-term perspective.</li>
</ul>
<p>Note: Opinions expressed are Jim Cramer's and may not reflect CNBC or affiliates' views.</p>
</body>
<body>
<!-- Signup Form -->
<form action="#" id="signup-form" method="post">
<input id="email" name="email" placeholder="Email Address" type="email"/>
<input type="submit" value="Sign Up"/>
</form>
<p> Reminder that AI-generated summary may be misleading or innaccurate due to malformed transcripts!</p> <br/><br/> <br/>
<!-- Footer -->
<footer id="footer">
<ul class="icons">
<li><a class="icon brands fa-twitter" href="#"><span class="label">Twitter</span></a></li>
<li><a class="icon brands fa-instagram" href="#"><span class="label">Instagram</span></a></li>
<li><a class="icon brands fa-github" href="#"><span class="label">GitHub</span></a></li>
<li><a class="icon fa-envelope" href="#"><span class="label">Email</span></a></li>
</ul>
<ul class="copyright">
<!-- <li>&copy; Untitled.</li> -->
<li>Credits for template: <a href="http://html5up.net">HTML5 UP</a></li>
</ul>
<!-- </footer> -->
<!-- Scripts -->
<script src="assets/js/main_test.js"></script>
</footer></body>
</html>